Lingrui Pharmaceutical H1 2026 Revenue RMB 2.148 Billion, Net Profit Up 4.36%
Lingrui Pharmaceutical released its semi-annual report for 2026, showing operating revenue of RMB 2.148 billion in the first half, up 2.32% year on year. Net profit attributable to shareholders rose 4.36% to RMB 495 million, with basic earnings per share of RMB 0.87. The results reflect steady growth in the company's core business during the period.
Lingrui Pharmaceutical disclosed its semi-annual report for 2026. The report shows that the company achieved operating revenue of RMB 2.148 billion in the first half of 2026, up 2.32% year on year. Net profit attributable to shareholders of the listed company reached RMB 495 million, an increase of 4.36% year on year. Basic earnings per share stood at RMB 0.87.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Traditional Chinese Medicine, with intensity 30/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.